Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands

Dementia and Geriatric Cognitive Disorders

Volumn 14, Issue 2, 2002, Pages 84-89

  Caro, J Jaime ^a,b,e   Salas, Maribel ^a   Ward, Alexandra ^a   Getsios, Denis ^c   Mehnert, Angelika ^d  

^a CARO RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Caro Research Institute   (Canada)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e NONE   (United States)

Author keywords

Alzheimer's dementia; Cholinesterase inhibitor; Costs; Economics; Galantamine; Modeling; The Netherlands

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HEALTH CARE SYSTEM; HUMAN; LONG TERM CARE; NETHERLANDS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; GALANTAMINE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; NETHERLANDS; NURSING HOMES; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 0036979073     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064929     Document Type: Article

References (41)

1. Breteler M, Ott A, Hofman A: The new epidemic: Frequency of dementia in the Rotterdam Study. Haemostasis 1998;28:117-123.
2. Koopmanschap MA, Polder JJ, Meerding WJ, Bonneux L, Van der Maas PJ: Costs of dementia in the Netherlands; in Wimo A, Jonsson B, Karlsson G, Winblad B (eds): Health Economics of Dementia. Chichester, Wiley & Sons, 1998, pp 207-214.
3. Ott A, Breteler M, van Harskamp F, Stijnen T, Hofman A: Incidence and risk of dementia: The Rotterdam Study. Am J Epidemiol 1998;147:574-580.
4. Meerding WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ: Demographic and epidemiologic determinants of healthcare costs in Netherlands: Cost of illness study. BMJ 1998;317:111-115.
5. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA, Tune LE: Diagnosis and treatment of Alzheimer's disease and related disorders. JAMA 1997;278:1363-1371.
6. Max W: Drug treatments for Alzheimer's disease: Shifting the burden of care. CNS Drugs 1999;11:363-372.
7. Maelicke A: Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11(suppl 1):11-18.
8. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomised, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268.
9. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group: Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: A multicentre, randomized controlled trial. BMJ 2001;321:1445-1449.
10. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C and the Galantamine USA-10 Study Group: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276.
11. Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai WY: Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997;227:806-812.
12. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13. Stern Y, Sano M, Paulson J, Mayeux R: Modified Mini-Mental State Examination: Validity and reliability. Neurology 1987;37(suppl 1):179.
14. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
15. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B: The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997;48:1511-1517.
16. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC: Health utilities in Alzheimer's disease: A cross sectional study of patients and caregivers. Med Care 1999;37:27-32.
17. MEDTAP TM International Inc: Costing Report II in Alzheimer (M2-2280), 1998, pp 7-10.
18. Academic Hospital Rotterdam, 1995.
19. Nationaal Ziekenhuisinstitut (NZI): Financiele Statistiek. Utrecht, NZI, 1991.
20. Tariff 1998: University Hospital of Rotterdam (UHR), i.e. Academic Hospital Rotterdam (AZR).
21. Korte kaart kosten-out internal medicine, Tariff 1998.
22. Korte kaart kosten-out internal medicine, Tariff 1996.
23. Tariff 1995: University Hospital of Rotterdam (UHR), i.e. Academic Hospital Rotterdam (AZR).
24. Tariff 1997/8: University Hospital of Rotterdam (UHR), i.e. Academic Hospital Rotter-dam (AZR).
25. Wilcock G, Wright T: Reminyl (galantamine) alleviates caregiver burden in Alzheimer's disease in two six month studies. 1st Int Quality Res in Dementia Conf, London, Nov 2000.
26. Farmacotherapeutisch Kompas, Ministry of Health, Netherlands, 1999.
27. Department of the Ministry of Economic Affairs: Statistics Netherlands. Costs of Dutch health care system in 1999, PR00-124, 1999.
28. Dijkstra A, Sipsma DH, Dassen TWN: Care dependency and survival among female patients with Alzheimer's disease: A two-year follow-up. Croat Med J 1998;39:365-370.
29. Boersma F, Ebfsting JA, Van den Brink, Tilburg W: Care services for dementia patients: Predictors for service utilization. Int J Geriatr Psychiatry 1997;12:1119-1126.
30. Van Der Roer N, Goes ES, Blom M, Busschbach JJ: Model of costs of care for dementia: Community-dwelling vs. institutionalization. Tijdschr Gerontol Geriatr 2000;31:55-61.
31. National Health Insurance Council (Ziekenfondsraad): Draft report on the pharmacoeconomic research guideline. Amsterdam, 1999.
32. Ringoir DJ, van Duuren R: Estimated health care expenditures for demented patients. Gerontologie 1981;12:28-37.
33. Ribbe MW: Care for the elderly: The role of the nursing home in the Dutch health care system. Int Psychogeriatr 1993;5:213-222.
34. Ribbe MW, Frijters DHM, Van Mens JT: Characteristics of nursing home patients at first admission: Age, sex and morbidity. Ned Tijdschr Geneeskd 1993;137:2544-2548.
35. Van Crevel H, van Gool WA, Walstra GJM: Early diagnosis of dementia: Which tests are indicated? What are their costs? J Neurol 1999;246:73-78.
36. van Dijk P, van de Sande HJ, Dippel DWJ, Habbema JDF: The nature of excess mortality in nursing home patients with dementia. J Gerontol 1992;47:M28-M34.
37. Olin J, Schneider L: Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev 2001;4:CD001747.
38. Lilienfeld S, Mehnert A: The long-term cognitive and functional benefits of galantamine in the treatment of Alzheimer's disease. 5th Congr Eur Fed Neurol Stud, Copenhagen, Oct 2000.
39. Blesa R: Galantamine: Therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000;11(suppl 1):28-34.
40. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D: Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-595.
41. Brouwer WB, van Exel NJ, Koopmanschap MA, Rutten FF: The valuation of informal care in economic appraisal: A consideration of individual choice and societal costs of time. Int J Technol Assess Health Care 1999;15:147-160.